Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taïdo Ménoactiv is a non-hormonal dietary supplement developed by Laboratoire ELERTE to manage symptoms associated with menopause. The formulation combines the plant extract *Cimicifuga racemosa* (Black Cohosh) with a complex of vitamins, including B6, B5, B9, B12, D3, and K2. *Cimicifuga racemosa* is traditionally used to alleviate vasomotor symptoms such as hot flashes and night sweats, likely through modulation of the serotonergic system. Vitamin B6 contributes to the regulation of hormonal activity, while Vitamins D3 and K2 work synergistically to maintain normal bone density, addressing the increased risk of osteoporosis in postmenopausal women. The supplement is administered orally and is intended for women seeking a non-hormonal alternative for menopausal transition support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Taïdo Ménoactiv.